Roche Holding AG Efficacy and Safety of Risdiplam in Patients with Type 2/3 Spinal Muscular Atrophy Presented at SMA Europe 2020 Call Transcript
Ladies and gentlemen, welcome to the Roche live audio webcast on efficacy and safety of the risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020. I'm Andre, the Chorus Call operator. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Karl Mahler, Head of Investor Relations. Please go ahead, sir.
Yes. Thanks a lot. So good afternoon and good morning, ladies and gentlemen. A warm welcome from our side for everybody who is on the webcast and online here to review the SUNFISH data we just have presented at the SMA Europe in Paris. With us is Paulo Fontoura, he's the Global Head of Neuroscience and Rare Diseases Clinical Development, who will lead us through the data. And on the phone, we also have Michael Ostland, the Lifecycle Leader for the SMA program. You will have the opportunity to ask questions after the presentation and allow me also to thank Gerard Tobin and Sabine Borngraber from our team to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
